Catalog10 refs
Livagen
BioregulatorsDigestiveResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
DNA/chromatin
Overview
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short peptide bioregulators developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed mechanism is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials.
Primary Uses
Hepatic support research
Gene-expression and chromatin studies
Cellular aging models
Liver resilience
Chromatin activation in lymphocytes
Digestive enzyme activity modulation
Neurodegenerative disorder research
Hepatoprotection
Hepatitis support (acute and chronic)
Liver fibrosis protection
Chromatin remodeling
Age-related liver decline
Gene activation
Immunomodulation
liver research
liver tissue support
Liver support
Immune function support
Chromatin reactivation in aged cells
Ribosomal gene reactivation
Protocol Reference
Dose
10–15 mg
Frequency
Daily
Half-life
Not Well Characterized
Route
Injection
Evidence
Preclinical / Moderate Research (disputed)
Research References· 10
https://pubmed.ncbi.nlm.nih.gov/37042594/
PubMedPMID 37042594- [https://www.mdpi.com/1420-3049/26/22/7053](https://www.mdpi.com/1420-3049/26/22/7053)
Research Models
DrosophilaHumanRat
Also in Bioregulators